Skip to main content
Premium Trial:

Request an Annual Quote

Centogene Partners With Aldeyra to Identify Rare Disease Patients

NEW YORK (GenomeWeb) – Centogene announced today that it has signed an agreement to help Aldeyra Therapeutics identify patients with Sjögren-Larsson Syndrome (SLS) in support of its effort to develop a treatment for the rare genetic disease.

SLS is caused by mutations that adversely affect lipid metabolism, leading to scaly skin, intellectual disability, and spasticity. While there is no approved treatment for the inherited disorder, Aldeyra currently has a drug candidate — reproxalap — under phase II development.

Under the terms of the agreement, Centogene will work with Aldeyra to identify SLS patients worldwide — including providing access to its CentoMD database of clinically annotated phenotype and genotype variants of rare diseases — and investigate the clinical spectrum of SLS.

"The partnership with Centogene complements the Aldeyra Registry for Patients with SLS, which was designed to unite patients and raise global awareness for the disease," Aldeyra Chief Medical Officer David Clark said in a statement. "Additionally, having access to Centogene's genetic database of patients with SLS demonstrates the critical role of genetics in identifying patients and developing medicines for diseases where treatments are nonexistent."

Earlier this month, Rostock, Germany-based Centogene signed a clinical development collaboration deal with Orphazyme to support clinical trials in India of a neuronopathic Gaucher disease treatment. And in late 2017, it agreed to integrate CentoMD into Qiagen's Clinical Insight bioinformatics platform and companion knowledge base to improve rare disease testing.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.